These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32597288)

  • 1. Costs of in-house genomic profiling and implications for economic evaluation: a case example of non-small cell lung cancer (NSCLC).
    Johnston KM; Sheffield BS; Yip S; Lakzadeh P; Qian C; Nam J
    J Med Econ; 2020 Oct; 23(10):1123-1129. PubMed ID: 32597288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer.
    Signorovitch J; Zhou Z; Ryan J; Anhorn R; Chawla A
    J Med Econ; 2019 Feb; 22(2):140-150. PubMed ID: 30430885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Budget Impact of Next-Generation Sequencing for Molecular Assessment of Advanced Non-Small Cell Lung Cancer.
    Yu TM; Morrison C; Gold EJ; Tradonsky A; Arnold RJG
    Value Health; 2018 Nov; 21(11):1278-1285. PubMed ID: 30442274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive genomic profiling for non-small-cell lung cancer: health and budget impact.
    Johnston KM; Sheffield BS; Yip S; Lakzadeh P; Qian C; Nam J
    Curr Oncol; 2020 Dec; 27(6):e569-e577. PubMed ID: 33380872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of next generation sequencing (NGS) testing in advanced cancer patients.
    Ortendahl JD; Cuyun Carter G; Thakkar SG; Bognar K; Hall DW; Abdou Y
    J Med Econ; 2024; 27(1):519-530. PubMed ID: 38466204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Budget Impact Analysis of Comprehensive Genomic Profiling in Patients With Advanced Non-Small-Cell Lung Cancer.
    Harvey MJ; Cunningham R; Sawchyn B; Montesion M; Reddy P; McBride A; Chawla AJ
    JCO Precis Oncol; 2021 Nov; 5():1611-1624. PubMed ID: 34994647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic Burden of Checkpoint Inhibitor Immunotherapy for the Treatment of Non-Small Cell Lung Cancer in US Clinical Practice.
    Nesline MK; Knight T; Colman S; Patel K
    Clin Ther; 2020 Sep; 42(9):1682-1698.e7. PubMed ID: 32747004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budget Impact Analysis of Comprehensive Genomic Profiling in Advanced Non-Small Cell Lung Cancer in Taiwan.
    Tsai YL; Chang CJ
    Value Health Reg Issues; 2023 May; 35():48-56. PubMed ID: 36863067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients.
    Patel YP; Husereau D; Leighl NB; Melosky B; Nam J
    Curr Oncol; 2021 Dec; 28(6):5278-5294. PubMed ID: 34940080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Micro-costing diagnostics in oncology: from single-gene testing to whole- genome sequencing.
    Pasmans CTB; Tops BBJ; Steeghs EMP; Coupé VMH; Grünberg K; de Jong EK; Schuuring EMD; Willems SM; Ligtenberg MJL; Retèl VP; van Snellenberg H; de Bruijn E; Cuppen E; Frederix GWJ
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):413-414. PubMed ID: 33852815
    [No Abstract]   [Full Text] [Related]  

  • 11. Costs of Next-Generation Sequencing Assays in Non-Small Cell Lung Cancer: A Micro-Costing Study.
    Kumar S; Bennett A; Campbell PA; Palidwor G; Lo B; Perkins TJ; Nochaiwong S; Sekhon HS; Stewart DJ; Thavorn K
    Curr Oncol; 2022 Jul; 29(8):5238-5246. PubMed ID: 35892985
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeted erlotinib for first-line treatment of advanced non-small cell lung cancer: a budget impact analysis.
    Bajaj PS; Veenstra DL; Goertz HP; Carlson JJ
    J Med Econ; 2014 Aug; 17(8):538-46. PubMed ID: 24716717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost Savings of Expedited Care with Upfront Next-Generation Sequencing Testing versus Single-Gene Testing among Patients with Metastatic Non-Small Cell Lung Cancer Based on Current Canadian Practices.
    Sheffield BS; Eaton K; Emond B; Lafeuille MH; Hilts A; Lefebvre P; Morrison L; Stevens AL; Ewara EM; Cheema P
    Curr Oncol; 2023 Feb; 30(2):2348-2365. PubMed ID: 36826141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities.
    Gutierrez ME; Choi K; Lanman RB; Licitra EJ; Skrzypczak SM; Pe Benito R; Wu T; Arunajadai S; Kaur S; Harper H; Pecora AL; Schultz EV; Goldberg SL
    Clin Lung Cancer; 2017 Nov; 18(6):651-659. PubMed ID: 28479369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utilization of genomic testing in advanced non-small cell lung cancer among oncologists in the Veterans Health Administration.
    Arney J; Helm A; Crook T; Braun UK; Chen GJ; Hayes TG
    Lung Cancer; 2018 Feb; 116():25-29. PubMed ID: 29413047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS).
    Andreas S; Chouaid C; Danson S; Siakpere O; Benjamin L; Ehness R; Dramard-Goasdoue MH; Barth J; Hoffmann H; Potter V; Barlesi F; Chirila C; Hollis K; Sweeney C; Price M; Wolowacz S; Kaye JA; Kontoudis I
    Lung Cancer; 2018 Oct; 124():298-309. PubMed ID: 29961557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Budget impact analysis of comprehensive genomic profiling for untreated advanced or recurrent solid cancers in Japan.
    Tang W; Hanada K; Motoo Y; Sakamaki H; Oda T; Furuta K; Abutani H; Ito S; Tsutani K
    J Med Econ; 2023; 26(1):614-626. PubMed ID: 37073487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer.
    Narita Y; Matsushima Y; Shiroiwa T; Chiba K; Nakanishi Y; Kurokawa T; Urushihara H
    Lung Cancer; 2015 Oct; 90(1):71-7. PubMed ID: 26259876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer.
    Carlson JJ; Wong WB; Veenstra DL; Reyes C
    J Med Econ; 2011; 14(2):159-66. PubMed ID: 21288059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.